Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Ondine Biomedical (LSE:OBI) FTSE AIM All-Share Small-Cap Stock in Focus on Cardiac Surgery Infection Economics

Key Highlights• Ondine Biomedical is in focus on 11 November 2026 after the company highlighted analysis estimating an average C$2,056 incremental cost per cardiac surgery associated with surgical-site infections and an estimated 10% loss of surgical capacity.• Investors are watching the next milestone, financial …

Ankur Sharma | 11 November 2026

BioPharma Credit (LSE:BPCR): FTSE All-Share Mid-Cap Healthcare Investment Trust Expands CorMedix Exposure

BioPharma Credit has entered into a senior securedLoanagreement with CorMedix under which the investment trust can provide up to US$50 million. A parallel vehicle can invest up to a further US$100 million, creating a totalFacilityof up to US$150 million across two tranches. CorMedix is …

Ankur Sharma | 11 November 2026

Frontier IP Group (LSE:FIPP): FTSE AIM All-Share Small-Cap IP Investor Gains Vaccine Research Catalyst

Frontier IP has highlighted a £500,000 grant awarded to portfolio company TheVaccineGroup and the Animal and Plant Health Agency for bovine respiratory syncytial virus vaccine research. The project builds on earlier trials in calves and is intended to determine the minimum effective dose and …

Ankur Sharma | 11 November 2026

Physiomics (LSE:PYC): FTSE AIM All-Share Micro-Cap Healthcare Stock Adds 14 Million Shares

Physiomics has moved into focus after 14 million new ordinary shares were scheduled for admission to AIM at 0.50 pence per share. Following admission, the enlargedShare Capitalis approximately 467.2 million ordinary shares. The company develops computational modelling tools intended to supportDrug Developmentand oncology decision-making.

Ankur Sharma | 11 November 2026

Renalytix (LSE:RENX): FTSE AIM All-Share Small-Cap Healthcare Stock Targets Fresh Investor Attention

Renalytix has announced its participation in the Mello2026 investor event on 17 November, with CEO James McCullough scheduled to present the company and its strategy. The company focuses on precision-medicine diagnostics for kidney disease, with its KidneyIntelX platform central to the commercial proposition.

Ankur Sharma | 11 November 2026

Nuformix (LSE:NFX) Respiratory Deal Sends Tiny Biotech Into Focus With Biovara Acquisition Plan

LSE:NFX trades on the Main Market and is associated with the Main Market. ItsMarket Valueis approximately £2.61 million, placing it in the small-cap segment under a broad UK market-cap framework.

Ankur Sharma | 11 November 2026

Novacyt (LSE:NCYT) FTSE AIM All-Share Small-Cap Stock in Focus as Yourgene DPYD Assay Expands

Key Highlights• Novacyt is in focus on 11 November 2026 after the company has continued to expand the Yourgene DPYD assayFranchiseafter its IVDR-certified commercial launch in Europe, with international market access remaining a key growth theme.• Investors are watching the next milestone, financial implications …

Ankur Sharma | 11 November 2026

Thalia Therapeutics (LSE:THAT) FTSE AIM All-Share Small-Cap Stock in Focus on Lipisiran Cardiovascular Programme

Key Highlights• Thalia Therapeutics is in focus on 11 November 2026 after the company has been advancing its RNA gene-silencing cardiovascular programme while continuing development of its broader RNA therapeutics pipeline.• Investors are watching the next milestone, financial implications and execution for LSE:THAT.Why Is …

Ankur Sharma | 11 November 2026

What Does the 11.4-Month Progression-Free Survival Signal for Faridoxorubicin Tell Investors About Avacta Group (LSE:AVCT), and What Must the FTSE AIM 100 Biotech Prove Next?

Avacta is a UK biotechnology company developing cancer therapies built on its pre|CISION platform. The platform attaches a cancer drug to a peptide that is cleaved by fibroblast activation protein, an enzyme found in high concentrations in the tissue surrounding many solid tumours. The …

Ankur Sharma | 11 November 2026

How has the £12.5m tender offer changed NIOX Group (LSE:NIOX), and what does it signal about the FTSE AIM 100 device maker's use of cash?

The company bought back 15,625,000 ordinary shares at 80p each, about 3.7% of its issued capital, and cancelled them. Following cancellation, the number of shares in issue and total voting rights stands at 405,241,313.

Ankur Sharma | 11 November 2026
Support

Hi! How can we help you today?

Loading…